<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03991000</url>
  </required_header>
  <id_info>
    <org_study_id>iCHF-2</org_study_id>
    <nct_id>NCT03991000</nct_id>
  </id_info>
  <brief_title>Iron in Patients With Cardiovascular Disease</brief_title>
  <acronym>iCHF-2</acronym>
  <official_title>Investigator-initiated, Randomized, Double-blind, Controlled, Multi-center Trial of Intrvenous Iron in Patients With Cardiovascular Disease and Concomitant Iron Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. med. Mahir Karakas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is now recognized that iron deficiency in cardiovascular disease contributes to impaired
      clinical outcome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The clinical trial is designed as a prospective, multi-centre, double-blind, randomised,
      controlled, interventional trial to investigate whether a therapy with i.v. iron (iron
      carboxymaltose) compared to saline can improve functional status across a subset of
      cardiovascular disease -namely acute myocardial infarction, atrial fibrillation, and heart
      failure with reduced ejection fraction.

      Iron administration will be carried out according to summary of product characteristics.
      Bolus administration (1000 mg) will be followed by an optional administration of 500-1000 mg
      within the first 4 weeks (up to a total of 2000 mg which is in-label) according to approved
      dosing rules, followed by administration of 500 mg iron carboxymaltose (over 15 minutes),
      except when haemoglobin is &gt; 16.0 g/dL or ferritin is &gt; 600 µg/L.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 28, 2019</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cohort A: Left-ventricular ejection fraction</measure>
    <time_frame>16 weeks</time_frame>
    <description>Change from baseline to week 16 in left-ventricular ejection fraction as determined by cardiac-MRI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohort B: Burden of atrial fibrillation</measure>
    <time_frame>12 months</time_frame>
    <description>Delta between treatment groups in burden of atrial fibrillation from day 90 to 365 as assessed by a routinely implanted event recorder.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohort C: Left-ventricular ejection fraction</measure>
    <time_frame>16 weeks</time_frame>
    <description>Change from baseline to week 16 in left-ventricular ejection fraction as determined by cardiac-MRI.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">480</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <condition>Anemia, Iron-deficiency</condition>
  <condition>Acute Myocardial Infarction</condition>
  <condition>Atrial Fibrillation</condition>
  <condition>Systolic Heart Failure</condition>
  <arm_group>
    <arm_group_label>Intravenous iron</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous iron administration in the form of ferric carboxymaltose will be carried out according to summary of product characteristics. Bolus administration (1000 mg) will be followed by an optional administration of 500-1000 mg within the first 4 weeks (up to a total of 2000 mg which is in-label) according to approved dosing rules, followed by administration of 500 mg ferric carboxymaltose at months 4 and 8, except when haemoglobin is &gt; 16.0 g/dL or ferritin is &gt; 600 µg/L. To avoid unblinding in these patients a saline infusion will be administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administration of i.v. NaCl according to the dosing rules for intravenous iron.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferric carboxymaltose</intervention_name>
    <description>Intravenous iron</description>
    <arm_group_label>Intravenous iron</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Saline application according to dosing rules of iron.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Cohort A (acute myocardial infarction): Acute Myocardial Infarction within 10 days
             (randomization/ first iron supplementation/ MRI must be performed within 10 days after
             AMI), without prior heart failure (defined as any known previous report of LVEF ≤ 45%)
             Cohort B (atrial fibrillation): Paroxysmal Atrial fibrillation or persistent AF Cohort
             C (heart failure): Left-ventricular ejection fraction ≤ 45 % (documented within the
             last 12 months prior to screening), all NYHA classes allowed

          2. Confirmed presence of iron deficiency (ferritin &lt; 100 ng/mL or ferritin 100 - 299
             ng/mL with transferrin saturation &lt; 20 %)

          3. Haemoglobin ≤ 15.5 g/dL

          4. Written informed consent

        Exclusion Criteria:

          1. Evidence of iron overload or disturbances in the utilisation of iron

          2. History of severe asthma, eczema or other atopic allergy

          3. History of immune or inflammatory conditions (e.g. systemic lupus erythematosus,
             rheumatoid arthritis)

          4. Use of renal replacement therapy

          5. Treatment with an erythropoietin stimulating agent (ESA), any i.v. iron and/or a blood
             transfusion in the previous 4 weeks prior to randomisation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mahir Karakas, MD, MBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Heart Center Hamburg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mahir Karakas, MD, MBA</last_name>
    <phone>+4915222817493</phone>
    <email>m.karakas@uke.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Berlin, Campus Benjamin-Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ulf Landmesser, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Heart Center Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mahir Karakas, MD, MBA</last_name>
      <phone>+4915222817493</phone>
      <email>m.karakas@uke.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sinisa Markovic, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 17, 2019</study_first_submitted>
  <study_first_submitted_qc>June 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2019</study_first_posted>
  <last_update_submitted>June 17, 2019</last_update_submitted>
  <last_update_submitted_qc>June 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Universitätsklinikum Hamburg-Eppendorf</investigator_affiliation>
    <investigator_full_name>Dr. med. Mahir Karakas</investigator_full_name>
    <investigator_title>Coordinating Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Iron deficiency</keyword>
  <keyword>Atrial fibrillation</keyword>
  <keyword>Acute myocardial infarction</keyword>
  <keyword>Systolic heart failure</keyword>
  <keyword>Anemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Heart Failure, Systolic</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

